학술논문
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
Document Type
Article
Author
Source
In: American Journal of Hematology . (American Journal of Hematology, May 2024, 99(5):880-889)
Subject
Language
English
ISSN
10968652
03618609
03618609